Skip to main content
Christopher B. Hansen
Rating: 5.0 of 5
( out of 1163 reviews )

Christopher B. Hansen, MD

Languages spoken: English, French

Clinical Locations

Primary Location

Midvalley Health Center Dermatology

Dermatology
243 East 6100 South
Murray , UT 84107
  • Christopher B. Hansen, MD has specialized expertise in the evaluation and treatment of rheumatic skin diseases such as lupus erythematosus, dermatomyositis, and scleroderma. He is board certified in Dermatology. Dr. Hansen’s main clinical focus is the medical management of connective tissue diseases that involve the skin as well as common skin disorders such as acne, rashes, and skin cancer. Dr. Hansen runs the UVA-1 phototherapy program in the Department of Dermatology. UVA-1 phototherapy is primarily used to treat patients with sclerosing skin disorders like morphea.

    Board Certification

    American Board of Dermatology (Dermatology)

    Patient Rating

    Rating: 5.0 out of 5
    5.0 /5
    ( out of 1163 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    December 30, 2025
    MIDVALLEY
    Rating: 5 out of 5

    he is kind and a good listener. Very professional and he explains things clearly.

    December 20, 2025
    MIDVALLEY
    Rating: 5 out of 5

    Great doctor. Very easy to talk with about my care.

    December 20, 2025
    MIDVALLEY
    Rating: 5 out of 5

    None better than- highest recommendation

    December 19, 2025
    MIDVALLEY
    Rating: 5 out of 5

    Smart, caring, personable. Can't get better.

    December 18, 2025
    MIDVALLEY
    Rating: 5 out of 5

    Very knowledgeable and respectful

    December 16, 2025
    MIDVALLEY
    Rating: 5 out of 5

    Smooth scheduling, no wait, and both assistant and doctor were thorough.

    December 14, 2025
    MIDVALLEY
    Rating: 5 out of 5

    Great bedside manner. Very personable and inquisitive. He's very knowledgeable in his field of expertise.

    December 13, 2025
    MIDVALLEY
    Rating: 5 out of 5

    Dr. Hansen is professional and direct with questions and answers. He provided me with great care and follow up

    December 13, 2025
    MIDVALLEY
    Rating: 5 out of 5

    Fully confident in the medical care I receive from Dr. Hansen.

  • Christopher B. Hansen, MD has specialized expertise in the evaluation and treatment of rheumatic skin diseases such as lupus erythematosus, dermatomyositis, and scleroderma. He is board certified in Dermatology. Dr. Hansen’s main clinical focus is the medical management of connective tissue diseases that involve the skin as well as common skin disorders such as acne, rashes, and skin cancer. Dr. Hansen runs the UVA-1 phototherapy program in the Department of Dermatology. UVA-1 phototherapy is primarily used to treat patients with sclerosing skin disorders like morphea.

    Board Certification and Academic Information

    Academic Departments Dermatology -Associate Professor (Clinical)
    Board Certification
    American Board of Dermatology (Dermatology)

    Education history

    Chief Resident Dermatology - University of Texas Southwestern Chief Resident
    Residency Dermatology - University of Texas Southwestern Medical School Resident
    Internship Internal Medicine - University of Utah School of Medicine Intern
    Research Fellow Dermatology - University of Utah - Dermatology Research Fellow
    Professional Medical Medicine - University of Utah M.D.
    Undergraduate French - University of Utah B.A.

    Selected Publications

    Journal Article

    1. Seifert RM, Noot CH, Sahni VN, Jimenez A, Gray L, Hopkins ZH, Frech TM, Hansen CB (2025). Ultraviolet A1 Phototherapy for Improvement of Hand Function in Scleroderma: A Blinded Prospective Study. Br J Dermatol. (Read full publication)
    2. Seifert RM, Teames CR, Sahni V, Noot C, deShazo RA, Powell DL, Rhoads JLW, Clarke JT, Hansen CB, Zone JJ, Hull CM, Hopkins ZH (2025). The impact of allergen avoidance on oral lichen planus: A retrospective cohort-based comparison. J Am Acad Dermatol. (Read full publication)
    3. Stone CJ, Broadbent E, Sahni VN, Gray L, Clarke JT, Hansen CB, Rhoads JLW, Zone JJ, Hull CM, Wu YP, Kean J, Secrest AM, Hopkins ZH (2025). Use of the Connor-Davidson Resilience Scale in a complex medical dermatology clinic: Cross-sectional study evaluating associations between resilience, health-related quality of life, and mental health. . J Am Acad Dermatol, S0190-9622(25)00389-5. doi: 10.1016/j.jaad.2025.02.082(1), 252-255. (Read full publication)
    4. Sahni V, Teames C, Seifert R, Conley M, deShazo R, Powell D, Rhoads JLW, Clarke JT, Hansen CB, Zone JJ, Hull CM, Hopkins ZH (2025). The association between skin allergy testing and oral squamous cell carcinoma in oral lichen planus: a retrospective cohort study. Arch Dermatol Res, 317(1), 207. (Read full publication)
    5. Esquivel ACF, Hansen CB (2024). Neurosensory symptoms and muscle cramping in morphea: A cross-sectional study and review. Skin Health Dis, 4(6), e453. (Read full publication)
    6. Herron E, Powell D, Hansen, C (2024). Drug-induced dermatomyositis following COVID 19 vaccination. Dermatol Online J, 30(2).
    7. Hopkins ZH, Jimenez A, Taliercio VL, Clarke JT, Hansen CB, Hull CM, Rhoads JLW, Zone JJ, Sahni VN, Kean J, Secrest AM (2024). Skin-Related Quality of Life During Autoimmune Bullous Disease Course. JAMA Dermatol, 159(11), 1185-1194. (Read full publication)
    8. Marcelus C, Jimenez A, Zussman J, Hansen CB, Sontheimer RD (2022). Questions raised by a case of adult-onset linear nodular scleroderma. Dermatol Online J, 28(5). (Read full publication)
    9. Overbury RS, Stoddard GJ, Pupaibool J, Hansen CB, Lebiedz-Odrobina D (2021). The effect of an electronic medical record intervention on hydroxychloroquine prescribing habits and surveyed providers' opinions of the 2016 American Academy of Ophthalmology guidelines in the rheumatology and dermatology practices of an academic institutionle. BMC Health Serv Res, 21(1), 913. (Read full publication)
    10. Beshay A, Zussman J, Hansen C (2020). Recurrent erythematous patch on the upper arm. JAAD Case Rep, 6(12), 1214-1216. (Read full publication)
    11. Winchester D, Duffin KC, Hansen C (2012). Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus, 21(9), 1007-10. (Read full publication)
    12. Hansen CB, Dahle KW (2012). Cutaneous lupus erythematosus. Dermatol Ther, 25(2), 99-111. (Read full publication)
    13. Gammon B, Hansen C, Costner MI (2011). Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol, 65(4), 717-721.e2. (Read full publication)
    14. Lowe GC, Henderson CL, Grau RH, Hansen CB, Sontheimer RD (2011). A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol, 164(3), 465-72. (Read full publication)
    15. Hansen CB, Callen JP (2010). Connective tissue panniculitis: lupus panniculitis, dermatomyositis, morphea/scleroderma. Dermatol Ther, 23(4), 341-9. (Read full publication)

    Review

    1. Sahni VN, Yim R, Amanullah A, Sahni D, Powell D, deShazo R, Rhoads JLW, Clarke JT, Hansen CB, Zone JJ, Hull CM, Hopkins ZH (2025). An Allergy-Based Approach to Orofacial Granulomatosis: A Narrative Review. [Review]. Dermatitis. (Read full publication)

    Case Report

    1. Shah A, Bowen A, Hansen C (2020). Multifocal periungual granulation tissue related to ibrutinib therapy. JAAD Case Rep, 6(2), 149-151. (Read full publication)

    Letter

    1. Westerdahl S, Hull CM, Clarke JT, Hansen CB, Rhoads JLW (2020). A single-center, retrospective record review of malignancy prevalence in patients with dermatomyositis with anti-transcription intermediary factor 1γ antibodies via line immunoassay versus immunoprecipitation. [Letter to the editor]. J Am Acad Dermatol, 84(2), 559-561. (Read full publication)
    2. Gonzalez CD, Hansen C, Clarke JT (2019). Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study. [Letter to the editor]. J Am Acad Dermatol, 81(3), 859-860. (Read full publication)